Data from the IMROZ study reportedly demonstrate for the first time that combining an anti-CD38 monoclonal antibody with standard treatment significantly improves progression-free survival in newly diagnosed transplant-ineligible multiple myeloma.
Sarculisa combination improves progression-free survival in newly diagnosed transplant-ineligible multiple myeloma patients
Leave a comment
